 Home > Medical News > Latest Medical News > Takeda's CMV drug Livtencity receives FDA approval and sales are expected to reach US$800 million

Takeda's CMV drug Livtencity receives FDA approval and sales are expected to reach US$800 million

 Last Update: 2022-01-03
 Source: Internet
 Author: User

Tags

fda approved protein powder

stem cell jobs

epilepsy natural treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationFan Dongdong

Recently, the US FDA has approved Takeda Livtencity (maribavir) to treat patients with cytomegalovirus (CMV) infection after transplantation in adults or children 12 years of age or older

In a phase 3 trial, compared with the conventional antiviral treatment selected by doctors, the proportion of patients with undetectable CMV DNA in the blood after 8 weeks of Livtencity treatment more than doubled.

Livtencity has similar efficacy between solid organ transplants and hematopoietic cell transplants

Livtencity was approved through the priority review process and was previously granted Orphan Drug Designation (ODD) and Breakthrough Drug Designation (BTD) by the FDA

Another part of Livtencity's market opportunity lies in its potential to enter the first-line treatment of CMV infection after transplantation

Takeda’s next major regulatory milestone may come from the dengue vaccine candidate TAK-003

Reference source: Takeda's post-transplant CMV drug Livtencity, shouldering $800M in sales expectations, scores FDA nod

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

united states logo(227)

ups united states(221)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.